Update Regarding Variant Strains of SARS-CoV-2

RHE-15557_COVID-19-Sell-Sheet_8.5x11_banner (1)

The CDC has identified SARS-CoV-2 variants that have been determined to be variants of public health concern.  Rheonix has conducted in silico analysis of the potential impact of these variants and has determined that they should not impact performance of the Rheonix COVID-19™ MDx assay.

WHO Label CDC Variant of Concern* Also Known As First Detected Impact to Rheonix COVID-19™ MDx Assay
Alpha B.1.1.7 20I/501Y.V1 United Kingdom No impact
Gamma P.1 20J/501Y.V3 Japan/Brazil No impact
Beta B.1.351 20H/501.V2 South Africa No impact
Epsilon B.1.427 20C/S:452R US-California No impact
Epsilon B.1.429 20C/S:452R US-California No impact
Delta B.1.617.2 20A/S:478K India No impact

*Source:  SARS-CoV-2 Variants of Concern | CDC

Rheonix continually monitors publicly available SARS-CoV-2 genetic sequences to identify the potential impact of variants on our assay performance.

Rheonix COVID-19™ MDx Assay Receives Expanded FDA Emergency Use Authorization to Include Saliva as a Sample Type.
Learn More